Long-term persistence of zoster vaccine efficacy

Clinical Infectious Diseases

Volumn 60, Issue 6, 2015, Pages 900-909

  Morrison, Vicki A ^a   Johnson, Gary R ^b   Schmader, Kenneth E ^c   Levin, Myron J ^d   Zhang, Jane H ^b   Looney, David J ^e   Betts, Robert ^f   Gelb, Larry ^g   Guatelli, John C ^e   Harbecke, Ruth ^e   Pachucki, Connie ^g   Keay, Susan ^h   Menzies, Barbara ^g   Griffin, Marie R ⁱ   Kauffman, Carol A ^j   Marques, Adriana ^k,n   Toney, John ^g   Boardman, Kathy ^l   Su, Shu Chih ^m   Li, Xiaoming ^m   Chan, Ivan S F ^m   Parrino, Janie ^m   Annunziato, Paula ^m   Oxman, Michael N ^e   Davis, L E ⁿ   Kauffman, C A ⁿ   Keay, S K ⁿ   Straus, S E ⁿ   Soto, N E ⁿ   Brunell, P ⁿ   Gnann, J W ⁿ   Serrao, R ⁿ   Cotton, D J ⁿ   Goodman, R P ⁿ   Arbeit, R D ⁿ   Pachucki, C T ⁿ   Levin, M J ^n,n   Schmader, K E ⁿ   Keitel, W A ⁿ   Greenberg, R N ⁿ   Morrison, V A ⁿ   Wright, P F ^n,n   Griffin, M R ^n,n   Simberkoff, M S ⁿ   Yeh, S S ⁿ   Lobo, Z ⁿ   Holodniy, M ⁿ   Loutit, J ⁿ   Betts, R F ^n,n   Gelb, L D ⁿ   Crawford, G E ⁿ   Guatelli, J ^n,n   Brooks, P A ⁿ   Looney, D J ⁿ   Neuzil, K M ⁿ   Toney, J F ⁿ   Menzies, B ⁿ   more..

^a UNIVERSITY OF MINNESOTA   (United States)

^b VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^c DUKE UNIVERSITY   (United States)

^d UNIVERSITY OF COLORADO   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF ROCHESTER   (United States)

^g VETERANS AFFAIRS MEDICAL CENTER   (United States)

^h UNIVERSITY OF MARYLAND   (United States)

ⁱ VANDERBILT UNIVERSITY   (United States)

^j UNIVERSITY OF MICHIGAN   (United States)

^k NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^l Ctrl Res Pharm Coord Center   (United States)

^m MERCK RESEARCH LABORATORIES   (United States)

ⁿ Merck and Co ^*

more..

Author keywords

Herpes zoster; Herpes zoster burden of illness; Herpes zoster vaccine; Persistence of vaccine efficacy; Postherpetic neuralgia

Indexed keywords

PLACEBO; VARICELLA ZOSTER VACCINE; VACCINE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE SURVEILLANCE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HERPES ZOSTER; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; POSTHERPETIC NEURALGIA; PRIORITY JOURNAL; RECIPIENT; VACCINATION; COMPLICATION; COST OF ILLNESS; EPIDEMIOLOGICAL MONITORING; IMMUNOLOGY; MIDDLE AGED; NEURALGIA, POSTHERPETIC; VERY ELDERLY;

AGED; AGED, 80 AND OVER; COST OF ILLNESS; EPIDEMIOLOGICAL MONITORING; FEMALE; FOLLOW-UP STUDIES; HERPES ZOSTER; HERPES ZOSTER VACCINE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NEURALGIA, POSTHERPETIC; VACCINATION; VACCINE POTENCY;

EID: 84929884631     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu918     Document Type: Article

References (24)

1. Hope-Simpson RE. The nature of herpes zoster. Proc R Soc Med 1965; 58:9-20.
2. Oxman MN, Levin MJ, Johnson GR, et al; for the Shingles Prevention Study Group. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005; 352:2271-84.
3. Oxman MN, Levin MJ; the Shingles Prevention Study Group. Vaccination against herpes zoster and postherpetic neuralgia. J Infect Dis 2008; 197:S228-36.
4. Schmader KE, Oxman MN, Levin MJ, et al; for the Shingles Prevention Study Group. Persistence of the efficacy of zoster vaccine in the Shingles Prevention Study and the short-term persistence substudy. Clin Infect Dis 2012; 55:1320-8.
5. Morrison VA, Oxman MN, Levin MJ, et al; for the Shingles Prevention Study Group. Safety of zoster vaccine in elderly adults following documented herpes zoster. J Infect Dis 2013; 208:559-63.
6. Harbecke R, Oxman MN, Arnold BA, et al. A real-time PCR assay to identify and discriminate among wild-type and vaccine strains of varicella-zoster virus and herpes simplex virus in clinical specimens, and comparison with the clinical diagnoses. J Med Virol 2009; 81:1310-22.
7. Schmader KE, Sloane R, Pieper C, et al. The impact of acute herpes zoster pain and discomfort on functional status and quality of life in older adults. Clin J Pain 2007; 23:490-6.
8. Coplan PM, Schmader K, Nikas A, et al. Development of a measure of the burden of pain due to herpes zoster and postherpetic neuralgia for prevention trials: adaptation of the brief pain inventory. J Pain 2004; 5:344-56.
9. Chang MN, Guess HA, Heyse JF. Reduction in burden of illness: A new efficacy measure for prevention trials. Stat Med 1994; 13:1807-14.
10. Guess HA, Lydick EG, Small RD, Miller LP. Exact binomial CIs for the relative risk in follow-up studies with sparsely stratified incidence density data. Amer J Epidemiol 1987; 125:340-7.
11. Guess HA, Thomas JE. A rapidly converging algorithm for exact binomial confidence intervals about the relative risk in follow-up studies with stratified incidence-density data. Epidemiol 1990; 1:75-7.
12. Martin DO, Austin H. Exact estimates for a rate ratio. Epidemiol 1996; 7:29-33.
13. SAS Software Inc. SAS, Version 9.1-9.2. Cary, NC: SAS Institute, 2002-2008.
14. Cytel Software Inc. StatXact, Version 8.0. Cambridge, MA: Cytel Software Inc, 2001.
15. Oxman MN, Williams HM, Levin MJ, et al. Efficacy of zoster vaccine according to dermatome region. In: Presented at Interscience Conference on Antimicrobial Agents and Chemotherapy, 16-19 December 2005; Washington, DC.
16. Simberkoff MS, Arbeit RD, Johnson GR, et al. Shingles Prevention Study Group. Safety of herpes zoster vaccine in the Shingles Prevention Study: A randomized trial. Ann Intern Med 2010; 152:545-54.
17. Ragozzino MW, Melton LJ 3rd, Kurland LT, Chu CP, Perry HO. Population-based study of herpes zoster and its sequelae. Medicine 1982; 61:310-6.
18. Leung J, Harpaz R, Molinari NA, Jumaan A, Zhou F. Herpes zoster incidence among insured persons in the United States, 1993-2006: evaluation of impact of varicella vaccination. Clin Infect Dis 2011; 52:332-40.
19. RussellML, Schopflocher DP, Svenson L, Virani SN. Secular trends in the epidemiology of shingles in Alberta. Epidemiol Infect 2007; 135:908-13.
20. Hales CM, Harpaz R, Joesoef MR, Bialek SR. Examination of links between herpes zoster incidence and childhood varicella vaccination. Ann Int Med 2013; 159:739-45.
21. Jumaan AO, Yu O, Jackson LA, Bohlke K, Galil K, Seward JF. Incidence of herpes zoster, before and after varicella-vaccination-associated decreases in the incidence of varicella, 1992-2002. J Infect Dis 2005; 191:2002-7.
22. Mullooly JP, Riedlinger K, Chun C,Weinmann S, Houston H. Incidence of herpes zoster, 1997-2002. Epidemiol Infect 2005; 133:245-53.
23. Gaillat J, Gajdos V, Launay O, et al. Does monastic life predispose to the risk of Saint Anthony's fire (herpes zoster)? Clin Infect Dis 2011; 53:405-10.
24. Crumpacker CS II. Absence of exposure to varicella does not increase the risk of zoster. Clin Inf Dis 2014; 53:411-2.